Compare CERS & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CERS | DHIL |
|---|---|---|
| Founded | 1991 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Investment Managers |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 319.2M |
| IPO Year | 1997 | 1995 |
| Metric | CERS | DHIL |
|---|---|---|
| Price | $2.05 | $170.00 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 39.3K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 3.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.21 |
| Revenue | ★ $199,191,000.00 | $149,665,296.00 |
| Revenue This Year | $25.31 | N/A |
| Revenue Next Year | $9.50 | N/A |
| P/E Ratio | ★ N/A | $9.82 |
| Revenue Growth | ★ 13.03 | 2.65 |
| 52 Week Low | $1.12 | $114.11 |
| 52 Week High | $2.25 | $171.43 |
| Indicator | CERS | DHIL |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 83.24 |
| Support Level | $1.83 | $168.51 |
| Resistance Level | $2.25 | $171.43 |
| Average True Range (ATR) | 0.14 | 2.20 |
| MACD | 0.02 | 6.73 |
| Stochastic Oscillator | 65.52 | 98.03 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.